"We know how important your vision is to you. And we know how important it is for you to continue seeing well for years to come. That’s why for more than 40 years, John-Kenyon has been the leader in quality eye care in Louisville and Southern Indiana. Each day, we look forward to helping our patients see better. Our experienced and caring team is here to treat all of your medical vision needs – from LASIK to Cataracts to Diabetic Retinopathy and more."

During the past decade, John Kenyon American Eye Institute conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 11 clinical trials were completed, i.e. on average, 122.2% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 6 clinical trials were completed. i.e. 600% of trials that started reached the finish line.

Out of the total clinical trials conducted in "John Kenyon American Eye Institute" #1 sponsor was "Jaeb Center for Health Research" with 15 trials, followed by "Allergan" with 3 trials sponsored, "Kala Pharmaceuticals, Inc." with 2 trials sponsored, "Bausch & Lomb Incorporated" with 1 trials sponsored and "Greater Houston Retina Research" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "John Kenyon American Eye Institute" #1 collaborator was "National Eye Institute (NEI)" with 13 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator, "Regeneron Pharmaceuticals" with 4 trials as a collaborator, "Allergan" with 3 trials as a collaborator and "National Institutes of Health (NIH)" with 2 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "John Kenyon American Eye Institute" are "Diabetic Macular Edema" (10 trials), "Diabetic Retinopathy" (8 trials), "Proliferative Diabetic Retinopathy" (4 trials), "Vitreous Hemorrhage" (3 trials) and "Dry Eye Disease" (2 trials). Many other conditions were trialed in "John Kenyon American Eye Institute" in a lesser frequency.

Most popular intervention types in "John Kenyon American Eye Institute" are "Drug" (22 trials), "Procedure" (6 trials), "Other" (3 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Ranibizumab" (3 trials), "Placebo" (2 trials), "0.3 mg intravitreal ranibizumab" (1 trials), "0.5-mg Ranibizumab" (1 trials) and "1.25 mg intravitreal bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "John Kenyon American Eye Institute" are 25 trials for "All" genders.

Currently, there are NaN active trials in "John Kenyon American Eye Institute". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in John Kenyon American Eye Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in John Kenyon American Eye Institute, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".